文献速递类风湿关节炎其他结缔组织病

利妥昔单抗或TNF抑制剂对类风湿关节炎相关支气管扩张症肺部感染与生存的影响

Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究为英国两中心10年回顾性观察队列,纳入接受RTX或TNFi治疗的RA-BR患者,评估RTX治疗后肺部感染加重情况并比较5年呼吸生存。结果显示RTX组因呼吸原因停药率低于TNFi组,校正5年呼吸生存更优(HR 0.40,95%CI 0.17,0.96,P=0.041),多数RTX治疗患者肺部症状稳定或改善。

要点

  • 800例RTX治疗RA患者中68例合并支气管扩张,患病率8.5%。
  • RTX治疗后新发支气管扩张3/735例,发生率0.4%。
  • RTX组因呼吸原因停药8/68(11.8%),TNFi组15/46(32.6%)。

核心结论

  • 多数RTX治疗的RA-BR患者长期随访中肺部症状稳定或改善。
  • RTX因不良肺部结局停药率低于匹配的TNFi队列。
  • 需要生物制剂时RTX是RA-BR可接受的治疗选择。

研究设计与样本

  • 英国两中心10年回顾性观察队列研究。
  • 纳入接受RTX或TNFi治疗的RA-BR患者。
  • 支气管扩张评估采用每年感染性加重次数。
  • 呼吸生存从治疗开始至因肺部加重或肺部相关死亡停药。

主要发现

  • 800例RTX治疗RA患者中68例有RA-BR,患病率8.5%。
  • RTX后新发支气管扩张3/735例,发生率0.4%。
  • 首次RTX周期后12个月,21/68(31%)加重次数少于前一年,36/68(53%)稳定,11/68(16%)加重增加。
  • 接受≥2个RTX周期者(n=60)中7/60(12%)加重增加,与低IgG、曲霉病及并发α1-抗胰蛋白酶缺乏相关。
  • RTX组因呼吸原因停药8/68(11.8%),TNFi组15/46(32.6%)。

关键数值与推荐

  • 支气管扩张感染性加重以每年加重次数评估。
  • 呼吸生存定义为从治疗开始至因肺部加重或肺部相关死亡停药。

临床怎么用

  • RA-BR患者需要生物制剂时,RTX可作为可接受的治疗选择。
  • RTX治疗后多数患者肺部加重稳定或改善,但需关注低IgG、曲霉病及α1-抗胰蛋白酶缺乏者加重风险。

局限性

  • 回顾性观察性队列设计。
  • 仅来自英国两个中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate rituximab (RTX) in patients with RA-associated bronchiectasis (RA-BR) and compare 5-year respiratory survival between those treated with RTX and TNF inhibitors (TNFi). METHODS: A retrospective observational cohort study of RA-BR in RTX or TNFi-treated RA patients from two UK centres over 10 years. BR was assessed using number of infective exacerbation/year. Respiratory survival was measured from therapy initiation to discontinuation either due to lung exacerbation or lung-related deaths. RESULTS: Of 800 RTX-treated RA patients, 68 had RA-BR (prevalence 8.5%). Post-RTX, new BR was diagnosed in 3/735 patients (incidence 0.4%). At 12 months post-Cycle 1 RTX, 21/68 (31%) patients had fewer exacerbations than the year pre-RTX, 36/68 (53%) remained stable and 11/68 (16%) had increased exacerbations. The rates of exacerbation improved after Cycle 2 and stabilized up to 5 cycles. Of patients who received ≥2 RTX cycles (n = 60), increased exacerbations occurred in 7/60 (12%) and were associated with low IgG, aspergillosis and concurrent alpha-1-antitrypsin deficiency. Overall, 8/68 (11.8%) patients discontinued RTX while 15/46 (32.6%) discontinued TNFi due to respiratory causes. The adjusted 5-year respiratory survival was better in RTX-treated compared with TNFi-treated RA-BR patients; HR 0.40 (95% CI 0.17, 0.96); P =0.041. CONCLUSION: The majority of RTX-treated RA-BR patients had stable/improved pulmonary symptoms in this long-term follow-up. In isolated cases, worsening of exacerbation had definable causes. Rates of discontinuation due to adverse lung outcomes were better for RTX than a matched TNFi cohort. RTX is an acceptable therapeutic choice for RA-BR if a biologic is needed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Iqbal K, Darby M, et al. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis. Rheumatology (Oxford). 2020. PMID: 32065634. doi:10.1093/rheumatology/kez676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。